Surveillance Epidemiology of Coronavirus Under Research Exclusion-Atopic Dermatitis (SECURE-AD)

NEA supports the efforts of the SECURE-DERM project to collect data on Covid-19 cases in patients with atopic dermatitis. Their physician-facing registry and patient survey collects observational data on Covid-19 outcomes in AD on a global scale to ultimately better understand the risk factors leading to poorer outcomes. Their registry and survey can be accessed HERE.

How does COVID-19 vaccination affect patients with eczema?

In 2020, the Surveillance Epidemiology of Coronavirus Under Research Exclusion-Atopic Dermatitis (SECURE-AD) Patient survey was launched to understand how COVID-19 infections impacted on patients with eczema. Preliminary results are available on the SECURE-AD website. In 2021, as we learn to live with COVID-19, the SECURE-AD Patient survey is adapting. We are now asking all patients with atopic eczema to complete the survey, whether they had COVID or not. The survey will provide insights into how the pandemic affected the eczema community and will give us more information about how COVID-19 vaccinations may affect patients with eczema. Please complete the survey, which is available here.